Medivir strengthens management team
This article was originally published in Scrip
Medivir, a research-based speciality pharma company focused on infectious diseases, has made several new appointments to its management team. Dr Maris Hartmanis joins the company as deputy CEO and COO, but will continue to work as CEO of Biophausia, which was recently acquired by Medivir. Professor Bertil Samuelsson, previously chief scientific officer, has been appointed chief scientific advisor focusing his efforts on the strategic development of Medivir's R&D. Dr Charlotte Edenius, previously vice-president of R&D, takes on the role of executive vice-president of R&D, and Dr Jens Kristensen has been appointed executive vice-president of the company's clinical unit. Dr Kristensen most recently served as vice-president of Karo Bio.